Previous 10 | Next 10 |
Amarin (NASDAQ: AMRN ) has lost its patent battle against generics. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality Amarin to Webcast Discussion of Presented Data March...
When most investors, including the pros, all agree on something, they're usually wrong. - Carl Icahn A common bioscience investment theme is a "market overreaction," especially during this coronavirus bear market. Driven by unreasonable fear, the market knocks down promising growth sto...
The novel coronavirus and the COVID-19 pandemic have raised a lot of fear and uncertainty in society and driven the stock market into bear territory. Nonetheless, I remain bullish on growth stocks for 2020, particularly at these prices. For those of us who remain optimistic about the market, som...
Amarin Corp. ( AMRN ) recently reported their Q4 2019 earnings with a strong beat on EPS and revenue. The company's flagship product, Vascepa, continues to establish a market by becoming an important tool in the battle against cardiovascular disease. Unfortunately, Amarin released its earnin...
The reaction to COVID-19 has created an interesting situation because of how the panic over the pandemic in the markets managed to nuke so many stocks in such an indiscriminate way. There doesn't seem to be a lot of rhyme or reason for the sell-off. Many investors are making a fear-based escape ...
As COVID-19 continues to spread, many companies and organizations are encouraging their employees to work remotely. This also applies to a number of U.S. regulatory bodies, including the U.S. Food and Drug Administration (FDA). On Wednesday, the FDA announced that due to many of its employees wo...
Biopharma company Amarin 's (NASDAQ: AMRN) recently approved fish-oil-based drug, Vascepa -- its sole product -- is expected by many analysts to become a blockbuster treatment for people at risk of heart attacks and strokes. However, with the COVID-19 pandemic dominating most people's co...
DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that eight presentations, including one Late-Breaking Science presentation and seven poster presentations, relevant to VASCEPA® (icosapent ethyl) and persiste...
A very quiet and tasteful way to be famous is to have a famous relative. Then you can not only be nothing, you can do nothing too ."- P. J. O'Rourke It was a wild week for investors as the markets went through their most volatile week of trading since the 2008 financial crisis. Sports lea...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...